Skip to main content
SpringerLink
Log in

Abnormal Uterine Bleeding

  • Chapter
Book cover Progestogens in Obstetrics and Gynecology

  • 1200 Accesses

Abstract

One of the most common gynecological consultations is for abnormal uterine bleeding. This condition accounts for up to 70 % of new gynecological consultations in perimenopausal women. After excluding organic causes, the mainstay of treatment is medical. Hormonal treatment usually includes some type of progestogen therapy. However, the treatment has to be “tailor made” depending on the patients age, desire for contraception or fertility, etc. In many cases in addition to progestogen, estrogen is often required to build the endometrioum, particularly in cases of a thinned endometrium due to ovarian dysfunction. Thus, the choice of progestogen needs also take into account the estrogenic, antiestrogenic, androgenic or anti-androgenic effects of the particular progestogen. In this chapter the pathophysiology, diagnosis and the resulting medical treatments of abnormal uterine bleeding are outlined.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Spencer CP, Whitehead MI. Endometrial assessment re-visited. Br J Obstet Gynaecol. 1999;106:623–32.

    Article  CAS  PubMed  Google Scholar 

  2. Lockwood CJ. Mechanisms of normal and abnormal endometrial bleeding. Menopause. 2011;18(4):408–11.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Krikun G, Schatz F, Lockwood CJ. Endometrial angiogenesis: from physiology to pathology. Ann N Y Acad Sci. 2004;1034:27–35.

    Article  CAS  PubMed  Google Scholar 

  4. Schatz F, Krikun G, Caze R, Rahman M, Lockwood CJ. Progestin-regulated expression of tissue factor in decidual cells: implications in endometrial hemostasis, menstruation and angiogenesis. Steroids. 2003;68:849–60.

    Article  CAS  PubMed  Google Scholar 

  5. Lockwood CJ, Nemerson Y, Guller S, Krikun G, Alvarez M, Hausknecht V, Gurpide E, Schatz F. Progestational regulation of human endometrial stromal cell tissue factor expression during decidualization. J Clin Endocrinol Metab. 1993;76:231–6.

    CAS  PubMed  Google Scholar 

  6. Lockwood CJ, Murk W, Kayisli UA, Buchwalder LF, Huang ST, Funai EF, Krikun G, Schatz F. Progestin and thrombin regulate tissue factor expression in human term decidual cells. J Clin Endocrinol Metab. 2009;94:2164–70.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Zini JM, Murray SC, Graham CH, Lala PK, Karikó K, Barnathan ES, Mazar A, Henkin J, Cines DB, McCrae KR. Characterization of urokinase receptor expression by human placental trophoblasts. Blood. 1992;79:2917–29.

    CAS  PubMed  Google Scholar 

  8. Papp C, Schatz F, Krikun G, Hausknecht V, Lockwood CJ. Biological mechanisms underlying the clinical effects of mifepristone (RU 486) on the endometrium. Early Pregnancy. 2000;4:230–9.

    CAS  PubMed  Google Scholar 

  9. Critchley HO, Jones RL, Lea RG, Drudy TA, Kelly RW, Williams AR, Baird DT. Role of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancy. J Clin Endocrinol Metab. 1999;84:240–8.

    CAS  PubMed  Google Scholar 

  10. Baird DT, Cameron ST, Critchley HO, et al. Prostaglandins and menstruation. Eur J Obstet Gynecol Reprod Biol. 1996;70(1):15–7.

    Article  CAS  PubMed  Google Scholar 

  11. Critchley HOD, Kelly RW, Brenner RM, et al. The endocrinology of menstruation – a role for the immune system. Clin Endocrinol. 2001;55:701–10.

    Article  CAS  Google Scholar 

  12. Dilley A, Drews C, Miller C, Lally C, Austin H, Ramaswamy D, Lurye D, Evatt B. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol. 2001;97:630–6.

    Article  CAS  PubMed  Google Scholar 

  13. James A, Matchar DB, Myers ER. Testing for von Willebrand disease in women with menorrhagia: a systematic review. Obstet Gynecol. 2004;104:381–8.

    Article  PubMed  Google Scholar 

  14. Parsons AK, Lense JJ. Sonohysterography for endometrial abnormalities: preliminary results. J Clin Ultrasound. 1993;21:87–95.

    Article  CAS  PubMed  Google Scholar 

  15. Epstein E, Ramirez A, Skoog L, et al. Transvaginal sonography, saline contrast sonohysterography and hysteroscopy for the investigation of women with postmenopausal bleeding and endometrium >5 mm. Ultrasound Obstet Gynecol. 2001;18:157–62.

    Article  CAS  PubMed  Google Scholar 

  16. Dueholm M, Lundorf E, Hansen ES, et al. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol. 2002;186:409–15.

    Article  PubMed  Google Scholar 

  17. Clark TJ, Voit D, Gupta JK, Hyde C, Song F, Khan KS. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. JAMA. 2002;288:1610–21.

    Article  PubMed  Google Scholar 

  18. Marret H, Fauconnier A, Chabbert-Buffet N, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol. 2010;152:133–7.

    Article  CAS  PubMed  Google Scholar 

  19. Dijkhuizen FP, De Vries LD, Mol BW, Brolmann HA, Peters HM, Moret E, et al. Comparison of transvaginal ultrasonography and saline infusion sonography for the detection of intracavitary abnormalities in premenopausal women. Ultrasound Obstet Gynecol. 2000;15:372–6.

    Article  CAS  PubMed  Google Scholar 

  20. Rodriguez GC, Yaqub N, King ME. A comparison of the Pipelle device and the Vabra aspirator as measured by endometrial denudation in hysterectomy specimens: the Pipelle device samples significantly less of the endometrial surface than the Vabra aspirator. Am J Obstet Gynecol. 1993;168:55–9.

    Article  CAS  PubMed  Google Scholar 

  21. Yarandi F, Izadi-Mood N, Eftekhar Z, et al. Diagnostic accuracy of dilatation and curettage for abnormal uterine bleeding. J Obstet Gynaecol Res. 2010;36:1049–52.

    Article  PubMed  Google Scholar 

  22. Goldstein SR. The role of transvaginal ultrasound or endometrial biopsy in the evaluation of the menopausal endometrium. Am J Obstet Gynecol. 2009;201(1):5–11.

    Article  PubMed  Google Scholar 

  23. Elsandabesee D, Greenwood P. The performance of Pipelle endometrial sampling in a dedicated postmenopausal bleeding clinic. J Obstet Gynecol. 2005;25:32–4.

    Article  CAS  Google Scholar 

  24. Kelekci S, Kaya E, Alan M, Alan Y, Bilge U, Mollamahmutoglu L. Comparison of transvaginal sonography, saline infusion sonography, and office hysteroscopy in reproductive-aged women with or without abnormal uterine bleeding. Fertil Steril. 2005;84:682–6.

    Article  PubMed  Google Scholar 

  25. Valenzano MM, Lijoi D, Mistrangelo E, Fortunato T, Costantini S, Ragni N. The value of sonohysterography in detecting intracavitary benign abnormalities. Arch Gynecol Obstet. 2005;272:265–8.

    Article  PubMed  Google Scholar 

  26. Goldstein SR, Zeltser I, Horan CK, Snyder JR, Schwartz LB. Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. Am J Obstet Gynecol. 1997;177:102–8.

    Article  CAS  PubMed  Google Scholar 

  27. Klehr-Bathmann I, Kuhl H. Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate. Maturitas. 1995;21:245–50.

    Article  CAS  PubMed  Google Scholar 

  28. Kuhnz W, Heuner A, Hümpel M, et al. In vivo conversion of norethisterone and norethisterone acetate to ethinyl estradiol in postmenopausal women. Contraception. 1997;56:379–85.

    Article  CAS  PubMed  Google Scholar 

  29. Mansour D. Safer prescribing of therapeutic norethisterone for women at risk of venous thromboembolism. J Fam Plann Reprod Health Care. 2012;38:148–9.

    Article  PubMed  Google Scholar 

  30. Chu MC, Zhang X, Gentzschein E, et al. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J Clin Endocrinol Metab. 2007;92:2205–7.

    Article  CAS  PubMed  Google Scholar 

  31. Lidegaard Ø, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011;343:d6423.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Kuhl H, Wiegratz I. Can 19-nortestosterone derivatives be aromatized in the liver of adult humans? Are there clinical implications? Climacteric. 2007;10:344–53.

    Article  CAS  PubMed  Google Scholar 

  33. Conard J, Plu-Bureau G, Bahi N, et al. Progestogen only contraception in women at high risk of venous thromboembolism. Contraception. 2004;70:437–41.

    Article  CAS  PubMed  Google Scholar 

  34. Gompel A, Carpentier S, Francès C, et al. Risk of venous thromboembolism and oral contraceptives. Lancet. 2002;359:1348–9.

    Article  CAS  PubMed  Google Scholar 

  35. Fulghesu AM, Magnini R, Piccaluga MP, Porru C. Ovulation induction in young girls with menometrorragia: a safe and effective treatment. Gynecol Endocrinol. 2014;30(2):117–20.

    Article  CAS  PubMed  Google Scholar 

  36. DeVore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding – a double-blind randomized control study. Obstet Gynecol. 1982;59:285–91.

    CAS  PubMed  Google Scholar 

  37. Munro MG, Mainor N, Basu R, Brisinger M, Barreda L. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. Obstet Gynecol. 2006;108:924–9.

    Article  CAS  PubMed  Google Scholar 

  38. American College of Obstetricians and Gynecologists. ACOG committee opinion no 557: management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. 2013;121:891–6.

    Article  Google Scholar 

  39. De Francicis P, Cobellis L, Fornaro F, Sepe E, Torella M, Colacurci N. Low-dose hormone therapy in the perimenopause. Int J Gynaecol Obstet. 2007;98:138–42.

    Article  Google Scholar 

  40. Kaunitz AM, Bissonnette F, Monteiro I, et al. Levonorgestrel-releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels. Contraception. 2012;86:452–7.

    Article  CAS  PubMed  Google Scholar 

  41. Kaunitz AM, Inki P. The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk review. Drugs. 2012;72:193–215.

    Article  CAS  PubMed  Google Scholar 

  42. Vilos GA, Marks J, Tureanu V, Abu-Rafea B, Vilos AG. The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleeding. J Minim Invasive Gynecol. 2011;18:75–80.

    Article  PubMed  Google Scholar 

  43. Lee NK, et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol. 2007;109(3):655–62.

    Article  PubMed  Google Scholar 

  44. Penner KR, Dorigo O, Aoyama C, Ostrzega N, Balzer BL, Rao J, et al. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecol Oncol. 2012;124:542–8.

    Article  PubMed  Google Scholar 

  45. Campagnoli C, Abba C, Ambroggio S, Brucato T, Pasanisi P. Life-style and metformin for the prevention of endometrial pathology in postmenopausal women. Gynecol Endocrinol. 2013;29:119–24.

    Article  PubMed  Google Scholar 

  46. Session DR, Kalli KR, Tummon IS, Damario MA, Dumesic DA. Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. Gynecol Endocrinol. 2003;17:405–7.

    Article  CAS  PubMed  Google Scholar 

  47. Tasci Y, Polat OG, Ozdogan S, et al. Comparison of the efficacy of micronized progesterone and lynestrenol in treatment of simple endometrial hyperplasia without atypia. Arch Gynecol Obstet. 2014;2:1.

    Article  Google Scholar 

  48. Gallos ID, Shehmar M, Thangaratinam S, Papapostolou TK, Coomarasamy A, Gupta JK. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010;203(6):547.

    Article  PubMed  Google Scholar 

  49. Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med. 1997;157(15):1651–6.

    Article  CAS  PubMed  Google Scholar 

  50. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas. 2008;61(1–2):171–80.

    Article  PubMed  Google Scholar 

  51. Mesci-Haftaci S, Ankarali H, Yavuzcan A, Caglar M. Endometrial curettage in abnormal uterine bleeding and efficacy of progestins for control in cases of hyperplasia. Asian Pac J Cancer Prev. 2014;15(8):3737–40.

    Article  PubMed  Google Scholar 

  52. Meden-Vrtovec H, Hren-Bozic M. Glandular cystic hyperplasia of the endometrium in the perimenopausal years. Acta Eur Fertil. 1988;19(1):49–52.

    CAS  PubMed  Google Scholar 

  53. Tasci Y, Polat OG, Ozdogan S, Karcaaltincaba D, Seckin L, Erkaya S. Comparison of the efficacy of micronized progesterone and lynestrenol in treatment of simple endometrial hyperplasia without atypia. Arch Gynecol Obstet. 2014;290(1):83–6.

    Article  CAS  PubMed  Google Scholar 

  54. El Behery MM, Saleh HS, Ibrahiem MA, Kamal EM, Kassem GA, El Sayed Mohamed M. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia. Reprod Sci. 2014. pii: 1933719114542014. [Epub ahead of print].

    Google Scholar 

  55. Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Hum Reprod. 2013;28(11):2966–71. Doi: 10.1093/humrep/det320. Epub 2013 Aug 23.

    Article  CAS  PubMed  Google Scholar 

  56. Abu Hashim H, Zayed A, Ghayaty E, El Rakhawy M. LNG-IUS treatment of non-atypical endometrial hyperplasia in perimenopausal women: a randomized controlled trial. J Gynecol Oncol. 2013;24(2):128–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  57. Ismail MT, Fahmy DM, Elshmaa NS. Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia. Reprod Sci. 2013;20(1):45–50.

    Article  CAS  PubMed  Google Scholar 

  58. Ravibabu K, Palla J, Chintada GS. A study of efficacy of ormeloxifene in the pharmacological management of dysfunctional uterine bleeding. J Clin Diagn Res. 2013;7(11):2534–6.

    PubMed Central  PubMed  Google Scholar 

  59. Bouchard P. Current and future medical treatments for menometrorrhagia during the premenopause. Gynecol Endocrinol. 2011;27 Suppl 1:1120–5.

    Article  CAS  PubMed  Google Scholar 

  60. Lethaby A, Duckitt K, Farquhar C. Non-steroidal antiinflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2013;1, CD000400.

    PubMed  Google Scholar 

  61. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev. 2000;(4). Art. No.: CD000249. DOI: 10.1002/14651858.CD000249.

  62. Lukes AS, Moore KA, Muse KN, Gersten JK, Hecht BR, Edlund M, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116:865–75.

    Article  PubMed  Google Scholar 

  63. Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid. Thromb Haemost. 2001;86:714–5.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, 52621, Israel

    Yochai Bar Shavit M.D.

  2. Department of Obstetrics & Gynecology, Sheba Medical Center, Tel Hashomer, 52621, Israel

    Jaron Rabinovici M.D. & Howard J. A. Carp M.B.B.S., F.R.C.O.G.

  3. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

    Jaron Rabinovici M.D. & Howard J. A. Carp M.B.B.S., F.R.C.O.G.

Authors
  1. Yochai Bar Shavit M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jaron Rabinovici M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Howard J. A. Carp M.B.B.S., F.R.C.O.G.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Howard J. A. Carp M.B.B.S., F.R.C.O.G. .

Editor information

Editors and Affiliations

  1. Tel Aviv University, Tel Aviv, Tel Aviv, Israel

    Howard J.A. Carp

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Shavit, Y.B., Rabinovici, J., Carp, H.J.A. (2015). Abnormal Uterine Bleeding. In: Carp, H. (eds) Progestogens in Obstetrics and Gynecology. Springer, Cham. https://doi.org/10.1007/978-3-319-14385-9_7

Download citation

Publish with us

Policies and ethics

Search

Navigation